Skip to main content

Table 4 Estimated change in cognitive function by follow-up time point and according to drug groups and municipality groups*

From: The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design

 

Estimated change (95% CI) versus baseline at

p-values

Groups

4 months

8 months,

12 months

P1

P2

MMSE

Drug groups

     

Placebo

−0.402 (−0.988, 0.185)

−0.015 (−0.584, 0.553)

−0.335 (−1.046, 0.375)

0.208

0.284

Donepezil

0.145 (−0.440, 0.730)

0.411 (−0.166, 0.988)

−0.470 (−1.181, 0.241)

  

Municipality groups

     

Standard care

0.198 (−0.429, 0.826)

0.790 ( 0.190, 1.389)

0.156 (−0.588, 0.901)

0.017

0.508

Stimulation

−0.380 (−0.933, 0.172)

−0.272 (−0.807, 0.262)

−0.841 (−1.510, -0.172)

  

Clock Drawing Test

Drug groups

     

Placebo

0.103 (−0.081, 0.288)

0.124 (−0.082, 0.330)

0.134 (−0.079, 0.347)

0.264

0.570

Donepezil

−0.016 (−0.200, 0.169)

−0.101 (−0.309, 0.107)

0.031 (−0.183, 0.245)

  

Municipality groups

     

Standard care

0.120 (−0.076, 0.317)

0.210 (−0.008, 0.428)

0.234 ( 0.011, 0.456)

0.071

0.257

Stimulation

−0.017 (−0.191, 0.158)

−0.144 (−0.339, 0.050)

−0.038 (−0.242, 0.165)

  

ADAS-cog

Drug groups

     

Placebo

−0.383 (−1.412, 0.646)

−1.126 (−2.201, -0.051)

−0.492 (−1.635, 0.650)

0.235

0.886

Donepezil

−1.027 (−2.053, -0.001)

−1.948 (−3.033, -0.862)

−1.510 (−2.661, -0.359)

  

Municipality groups

     

Standard care

−1.515 (−2.597, -0.433)

−1.736 (−2.889, -0.582)

−1.619 (−2.830, -0.407)

0.108

0.242

Stimulation

−0.069 (−1.030, 0.893)

−1.380 (−2.407, -0.352)

−0.493 (−1.590, 0.603)

  
  1. * Linear mixed models adjusted for baseline cognitive score.
  2. P1, p-value for overall equality of change between the groups.
  3. P2, p-value for test of interaction between group and time, i.e. test for constant differences between groups over time.